Scarica l'app Stockscreener
1.55
1.84%
0.028
Dopo l'orario di chiusura:
1.53
-0.02
-1.29%
Precedente Chiudi:
$1.522
Aprire:
$1.64
Volume 24 ore:
505.54K
Relative Volume:
0.56
Capitalizzazione di mercato:
$35.62M
Reddito:
-
Utile/perdita netta:
$-8.09M
Rapporto P/E:
-3.5599
EPS:
-0.4354
Flusso di cassa netto:
$-7.37M
1 W Prestazione:
+0.65%
1M Prestazione:
+16.54%
6M Prestazione:
+60.87%
1 anno Prestazione:
-1.90%
Intervallo 1D:
$1.51
$1.67
Intervallo di 1 settimana:
$1.45
$1.67
Portata 52W:
$0.85
$2.2299
NanoViricides Inc Stock (NNVC) Company Profile
Nome
NanoViricides Inc
Settore
Industria
Telefono
203-937-6137
Indirizzo
1 Controls Drive, Shelton, CT
Compare NNVC vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NNVC
NanoViricides Inc
|
1.55 | 35.39M | 0 | -8.09M | -7.37M | -0.4354 |
VRTX
Vertex Pharmaceuticals Inc
|
470.72 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
759.24 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
830.79 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
182.45 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
313.77 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
NanoViricides Inc Stock (NNVC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-16 | Iniziato | Alliance Global Partners | Buy |
| 2015-02-11 | Iniziato | Midtown Partners | Strong Buy |
NanoViricides Inc Borsa (NNVC) Ultime notizie
Ebola outbreak death toll tops 1,300 as drug trial awaits approval - Stock Titan
NanoViricides Inc (NNVC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
NanoViricides Inc (NNVC) Cash Flow - TradingKey
EDGAR Filing Documents for 0001104659-26-086797 - SEC.gov
Form 424B5 NanoViricides Inc For: 27 July By Investing.com - Investing.com Canada
Form 424B5 NANOVIRICIDES, INC. - StreetInsider
NNVC Stock Up 17% Today: What’s Driving The Rally? - Stocktwits
As Ebola Death Toll Surpasses 930 Within Two Months, NanoViricides Has Applied to the DR Congo Regulatory Agency for Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola - ACCESS Newswire
NanoViricides, Inc. Revenue Breakdown – AMEX:NNVC - TradingView
NanoViricides, Inc. (NNVC) Stock Price, News, Quote & History - Yahoo! Finance Canada
NanoViricides Inc (NNVC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
NNVC|NanoViricides Inc|Price:1.535|Chg%:+0.055 - TradingKey
NanoViricides Inc (NNVC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NanoViricides Inc (NNVC) Institutional Confidence - TradingKey
NanoViricides Raises $3.8 Million in Registered Direct Offering to Fund Antiviral Drug Development - citybuzz -
NanoViricides Announces Pricing of ~$3.8 Million Registered Direct Offering - Lelezard
NanoViricides prices offering with 2,516,339 warrants at US$ 1.75 exercise price - Bitget
NanoViricides Seeks Approval for Phase II Ebola Trial in DRC Amid Ongoing Outbreak - citybuzz -
NanoViricides (NYSE:NNVC) Draws Attention After Clinical Update - Kalkine Media
DRC Ebola outbreak tops 930 deaths; NanoViricides seeks trial approval - Stock Titan
Nanoviricides Company Profile & Introduction - Moomoo
NNVC Q2 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost Discipline Amid Pre-Revenue StageProfit Announcement - dars.gov.et
Form 424B5 NanoViricides Inc For: 17 July By Investing.com - Investing.com South Africa
Form 424B5 NanoViricides Inc For: 17 July - Investing.com UK
NanoViricides Establishes ATM Equity Sales Agreement - TipRanks
NanoViricides Inc. (NNVC) Q2 2026 Earnings: Narrowed Loss Beats Expectations; Stock RisesROE Trend Analysis - dars.gov.et
As the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of EbolaNanoViricides Proposal is Approved by the Pillar Committee in DR Congo - ACCESS Newswire
NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close - Treasure Coast News
Noble Financial Maintains Nanoviricides(NNVC.US) With Buy Rating, Maintains Target Price $6 - Moomoo
NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close - Treasure Coast News
NanoViricides Secures Ethics Approval for Phase II Ebola Trial in DRC - citybuzz -
As Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in Congo - ACCESS Newswire
Oral Ebola drug gummies clear key ethics hurdle as Congo outbreak widens - Stock Titan
NNVC Stock In The Limelight After This Analyst Sees A 350% Upside Potential – Everything To Know About Its Experimental Drug For Ebola - Stocktwits
NanoViricides Receives Outperform Rating and $6 Price Target from Noble Capital Markets - citybuzz -
NanoViricides Inc. (NNVC) Q2 2026 Earnings: EPS Beat but No Revenue; Stock Declines 1.01%Earnings Revision Upgrade - dars.gov.et
Research Analyst Report on NanoViricides Rates Company "Outperform"; Separately, A "Fireside Chat" Interview of the Company's President Dr. Anil Diwan Hosted by Mr. Dave Donlin was Published by StockInvestor Daily - ACCESS Newswire
symbol__ Stock Quote Price and Forecast - CNN
NanoViricides Price Target Announced at $6.00/Share by Noble Capital Markets - Moomoo
Noble Capital initiates NanoViricides stock with Outperform rating By Investing.com - Investing.com South Africa
Noble Financial Initiates Nanoviricides(NNVC.US) With Buy Rating, Announces Target Price $6 - Moomoo
NanoViricides Advances NV-387 Oral Gummies Toward Phase II Trial for Bundibugyo Ebola in DRC - citybuzz -
Noble Capital initiates NanoViricides stock with Outperform rating - Investing.com
As the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo - ACCESS Newswire
NanoViricides moves NV-387 oral gummies toward DRC Ebola trial - Stock Titan
Enterprise value to revenue forward of NanoViricides, Inc. – AMEX:NNVC - TradingView
NNVCNanoViricides Inc Website Traffic and Mobile Apps Usage - Finviz
Price to book forward of NanoViricides, Inc. – AMEX:NNVC - TradingView
Enterprise value to revenue forward of NanoViricides, Inc. – SWB:NV3P - TradingView
Enterprise value to EBITDA forward of NanoViricides, Inc. – AMEX:NNVC - TradingView
NNVC Q2 2026 Earnings: Narrower-than-Expected Loss as R&D Pipeline AdvancesEarnings Cycle Report - po-news-eg.net
NanoViricides Inc Azioni (NNVC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.84%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):